| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2268 | 57-66-9 |
| Dose | Unit | Route |
|---|---|---|
| 1 | g | O |
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 1.20 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 58.52 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 99 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.13 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.25 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.13 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 5.90 hours | Lombardo F, Berellini G, Obach RS |
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 26, 1951 | FDA |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Adenovirus infection | 62.70 | 44.50 | 12 | 417 | 3559 | 63485034 |
| Aplastic anaemia | 56.21 | 44.50 | 13 | 416 | 9556 | 63479037 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Adenovirus infection | 100.81 | 22.77 | 25 | 1079 | 5232 | 34950595 |
| Lip haemorrhage | 32.68 | 22.77 | 7 | 1097 | 763 | 34955064 |
| Platelet transfusion | 23.01 | 22.77 | 6 | 1098 | 1520 | 34954307 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Adenovirus infection | 166.73 | 23.98 | 37 | 1406 | 8410 | 79734535 |
| Aplastic anaemia | 62.91 | 23.98 | 20 | 1423 | 17885 | 79725060 |
| Pancreatitis acute | 33.99 | 23.98 | 17 | 1426 | 49587 | 79693358 |
| Lip haemorrhage | 33.50 | 23.98 | 7 | 1436 | 1187 | 79741758 |
| Cystitis haemorrhagic | 31.19 | 23.98 | 10 | 1433 | 9162 | 79733783 |
None
| Source | Code | Description |
|---|---|---|
| ATC | M04AB01 | MUSCULO-SKELETAL SYSTEM ANTIGOUT PREPARATIONS ANTIGOUT PREPARATIONS Preparations increasing uric acid excretion |
| MeSH PA | D000277 | Adjuvants, Pharmaceutic |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D006074 | Gout Suppressants |
| MeSH PA | D010592 | Pharmaceutic Aids |
| MeSH PA | D014528 | Uricosuric Agents |
| CHEBI has role | CHEBI:35841 | uricosuric drugs |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hyperuricemia | indication | 35885006 | DOID:1920 |
| Articular gout | indication | 48440001 | DOID:13189 |
| Chronic gouty arthritis | indication | 68451005 | |
| Adjunct Treatment to Inhibit Renal Drug Excretion | indication | ||
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Diarrhea | contraindication | 62315008 | |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Anemia due to enzyme deficiency | contraindication | 111577008 | |
| Disorder of muscle | contraindication | 129565002 | DOID:423 |
| Disease of blood AND/OR blood-forming organ | contraindication | 191124002 | DOID:74 |
| Impaired renal function disorder | contraindication | 197663003 | |
| Rhabdomyolysis | contraindication | 240131006 | |
| Renal dialysis | contraindication | 265764009 | |
| Infectious mononucleosis | contraindication | 271558008 | DOID:8568 |
| Uric acid renal calculus | contraindication | 274401005 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Aplastic anemia | contraindication | 306058006 | DOID:12449 |
| Bone marrow depression | contraindication | 307762000 | |
| Pseudomembranous enterocolitis | contraindication | 397683000 | |
| Granulocytopenic disorder | contraindication | 417672002 | |
| Vomiting | contraindication | 422400008 | |
| Uric Acid Nephropathy Gout | contraindication |
None
None
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.46 | acidic |
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Solute carrier family 22 member 11 | Transporter | INHIBITOR | IC50 | 4.26 | CHEMBL | CHEMBL | |||
| Solute carrier family 22 member 6 | Transporter | INHIBITOR | IC50 | 4.90 | IUPHAR | CHEMBL | |||
| Solute carrier family 22 member 8 | Transporter | INHIBITOR | IC50 | 5.05 | CHEMBL | CHEMBL | |||
| Solute carrier family 22 member 12 | Transporter | IC50 | 4.30 | CHEMBL | |||||
| UDP-glucuronosyltransferase 1-7 | Enzyme | Ki | 4.02 | CHEMBL | |||||
| Carbonic anhydrase 9 | Enzyme | Ki | 6.44 | CHEMBL | |||||
| Carbonic anhydrase 12 | Enzyme | Ki | 5.90 | CHEMBL | |||||
| Carbonic anhydrase 2 | Enzyme | Ki | 6.37 | CHEMBL | |||||
| Solute carrier family 22 member 6 | Transporter | Ki | 5.20 | CHEMBL | |||||
| Solute carrier family 22 member 20 | Transporter | Ki | 5.08 | CHEMBL | |||||
| Transient receptor potential cation channel subfamily V member 2 | Ion channel | ACTIVATOR | EC50 | 4.50 | IUPHAR |
| ID | Source |
|---|---|
| 4017872 | VUID |
| N0000146225 | NUI |
| D00475 | KEGG_DRUG |
| 4017872 | VANDF |
| C0033209 | UMLSCUI |
| CHEBI:8426 | CHEBI |
| RTO | PDB_CHEM_ID |
| CHEMBL897 | ChEMBL_ID |
| DB01032 | DRUGBANK_ID |
| D011339 | MESH_DESCRIPTOR_UI |
| 4911 | PUBCHEM_CID |
| 4357 | IUPHAR_LIGAND_ID |
| 563 | INN_ID |
| PO572Z7917 | UNII |
| 8698 | RXNORM |
| 128 | MMSL |
| 5356 | MMSL |
| d00031 | MMSL |
| 002321 | NDDF |
| 387365004 | SNOMEDCT_US |
| 66094001 | SNOMEDCT_US |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Probenecid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1367 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 13 sections |
| Probenecid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1367 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 13 sections |
| Probenecid and Colchicine | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0591-5325 | TABLET | 500 mg | ORAL | ANDA | 13 sections |
| Probenecid and Colchicine | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0591-5325 | TABLET | 500 mg | ORAL | ANDA | 13 sections |
| Probenecid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-5347 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 12 sections |
| Probenecid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-5347 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 12 sections |
| Probenecid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-541 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 14 sections |
| Probenecid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-541 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 14 sections |
| Probenecid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 11819-282 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 12 sections |
| Probenecid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-839 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 14 sections |
| Probenecid and Colchicine | Human Prescription Drug Label | 2 | 50742-263 | TABLET | 500 mg | ORAL | ANDA | 13 sections |
| Probenecid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-0159 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 12 sections |
| Probenecid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8213 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 12 sections |
| Probenecid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-1993 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 13 sections |
| Probenecid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69367-154 | TABLET | 500 mg | ORAL | ANDA | 13 sections |
| Probenecid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71335-1697 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 13 sections |
| Probenecid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71626-999 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 13 sections |
| Probenecid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 83008-020 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 14 sections |